Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chengdu Hoist Wins Approval for Liver Cancer Drug

publication date: Jun 8, 2007
Drug Combines Monoclonal Antibody and Radioactive Iodine -- Chengdu Hoist Inc. Ltd. received the State Food and Drug Administration's approval to begin marketing a new treatment for hepatocellular (liver) cancer. The drug is an iodine (131I) metuximab injection that is indicated for patients whose liver cancer cannot be operated on or who have relapsed following earlier therapies.Chengdu Hoist received new drug approval, production approval and a GMP certificate from the State Food and Drug Administration at the end of 2006. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here